NCT04774380 - Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer | Biotech Hunter

Enrollment

152

Participants

Timeline

Start Date

November 11, 2021

Primary Completion Date

June 12, 2023

Study Completion Date

January 2, 2025

Conditions

Extensive-stage Small Cell Lung Cancer

Interventions

DRUG

Durvalumab

Participants will receive durvalumab via IV infusion on Day 1 of each cycle.

DRUG

Cisplatin

Participants will receive cisplatin via IV administration on Day 1 of each cycle.

DRUG

Carboplatin

Participants will receive carboplatin via IV administration Day 1 of each cycle.

DRUG

Etoposide

Participants will receive etoposide via IV administration on days 1 to 3 of each cycle.

Trial Locations (35)

1303

Research Site, Sofia

1330

Research Site, Sofia

1407

Research Site, Sofia

4500

Research Site, Panagyurishte

7002

Research Site, Rousse

10043

Research Site, Orbassano

12351

Research Site, Berlin

13125

Research Site, Berlin

16059

Research Site, Bursa

20070

Research Site, Pamukkale

20141

Research Site, Milan

20251

Research Site, Hamburg

22030

Research Site, Edirne

34098

Research Site, Istanbul

34125

Research Site, Kassel

34722

Research Site, Istanbul

35100

Research Site, Izmir

44280

Research Site, Malatya

51109

Research Site, Cologne

54290

Research Site, Adapazarı

60126

Research Site, Ancona

70124

Research Site, Bari

80131

Research Site, Napoli

82131

Research Site, Gauting

90146

Research Site, Palermo

H4A 3J1

Research Site, Montreal

180 81

Research Site, Burgas

779 00

Research Site, Olomouc

703 00

Research Site, Ostrava

07747

Research Site, Jena

00168

Research Site, Roma

06010

Research Site, Ankara

06100

Research Site, Ankara

06800

Research Site, Ankara

07070

Research Site, Antalya